Clinical Trials Logo
  1. Home
  2. Carcinoma, Transitional Cell
  3. NCT00191971

2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen

Urologic Neoplasms Clinical Trial

Official title:
A Phase II Study of Gemcitabine in Transitional Cell Carcinoma of the Urothelium

Clinical Trial Summary

To investigate efficacy and safety of 2nd line GEM monotherapy after CDDP regimen for patients with transitional cell carcinoma of urothelium

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00191971
Study type Interventional
Source Eli Lilly and Company
Contact
Status Completed
Phase Phase 2
Start date January 2004
Completion date September 2006
View Details
See also
  Status Clinical Trial Phase
Completed NCT00151034 - Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer Phase 2
Completed NCT04933604 - LPN in Patients With High-complex Renal Tumors
Completed NCT03219333 - A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Phase 2
Completed NCT04052113 - Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer
Terminated NCT02543645 - A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Phase 1
Completed NCT01454089 - A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer Phase 2
Active, not recruiting NCT03288545 - A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer Phase 1/Phase 2
Not yet recruiting NCT05025930 - Evaluate the Safety and Effectiveness of the Endoscopic Surgical Instrument Control System (SP1000). N/A
Not yet recruiting NCT05135520 - Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Kidney Specimen N/A
Withdrawn NCT04630483 - Platelet-lymphocyte and Neutrophil-lymphocyte Ratio in Patients Undergoing Cancer Surgery
Terminated NCT02386111 - A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma Phase 1
Completed NCT03081858 - Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT04644432 - Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma Phase 2
Recruiting NCT05308771 - To Investigate the Use of a New Syringe "Visual Pressure Control (VPC)" for Epidural Anesthesia in Children Surgery N/A
Terminated NCT00226954 - Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer Phase 2
Completed NCT05113134 - Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Specimen N/A
Completed NCT04213157 - Laparoscopic Partial Nephrectomy for cT1 Tumors
Completed NCT02780687 - Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy Phase 2
Recruiting NCT04922047 - Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) Phase 1/Phase 2
Not yet recruiting NCT06353906 - Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer Phase 2